| amantadine / Generic mfg. |
2011-005201-75: Impact d’un traitement PREcoce par aMANtadine sur les DYSKinésies induites par la L-DOPA dans la maladie de Parkinson : étude comparative avec tirage au sort versus placebo. |
|
|
| Ongoing | 2 | 202 | Europe | amantadine, Capsule, mantadix | CHU de Toulouse, Programme Hospitalier de Recherche Clinique, Enveloppe Nationale 2011 | Maladie de Parkinson, Maladie de Parkinson, Diseases [C] - Nervous System Diseases [C10] | | | | |
ChiCTR-TRC-12002299: Changes of fMRI and EEG stimulating-reaction of patients in vegetative state or minimal consciousness state after treating by amantadine or levodopa |
|
|
| Completed | 2 | 25 | | amantadine ;levodopa ;No treatment | Department of Neurology, Xijing Hospital, the Fourth Military Medical University; Xijing Hospital, selffinancing | patients in vegetative state or minimal consciousness state | | | | |
| Active, not recruiting | 2 | 18 | Europe | Amantadine Sulfate, physiological saline (0.9% NaCl solution) | Azienda Sanitaria dell'Alto Adige | Amantadine, Consciousness Disorders, Electroencephalography | 01/24 | 09/24 | | |
NCT03612921: Oral Amantadine, IV Amantadine and Hemodynamic Response to Laryngoscopy |
|
|
| Recruiting | 2 | 60 | RoW | oral Amantadine sulfate, amantadine, i.v Amantadine Sulfate, PK-Merz, placebo tablet | Assiut University | Intubation, Intratracheal | 03/22 | 04/22 | | |
2022-002418-18: AmaNtadine for NeuroenhancEment in acutE patients Study - A prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES) |
|
|
| Not yet recruiting | 2 | 50 | Europe | Amantadin-ratiopharm®, Infusion, Amantadin-ratiopharm® | University Hospital Tübingen, University Hospital Tuebingen | Patients on Intermediate Care and Intensive Care Unit (IMC and ICU) with unresponsive wakefulness syndrome not otherwise explained, Patients on Intermediate Care and Intensive Care Unit (IMC and ICU) with unresponsive wakefulness syndrome not otherwise explained, Not possible to specify | | | | |
NCT05667077: The Effect of Amantadine on Post-COVD-19 Fatigue |
|
|
| Not yet recruiting | 2 | 83 | RoW | Amantadine | Shahid Beheshti University of Medical Sciences | Post-COVID-19 Syndrome | 12/22 | 01/23 | | |
| Recruiting | 2 | 50 | Europe | Amantadine | University Hospital Tuebingen | Disorder of Consciousness | 10/24 | 12/24 | | |
| Recruiting | 2 | 60 | US | Amantadine, Placebo | University of Pennsylvania | Stroke, Ischemic, Stroke Hemorrhagic | 12/25 | 06/26 | | |
MR-301-T-001, NCT06253923: Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI). |
|
|
| Recruiting | 2 | 45 | US | Amantadine Hydrochloride, Placebo | SHINKEI Therapeutics, Inc, Duke Clinical Research Institute | Traumatic Brain Injury | 09/24 | 11/24 | | |
NCT06234462: A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid |
|
|
| Recruiting | 2 | 30 | US | Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications for symptoms management | University of Texas Southwestern Medical Center | Long COVID, Post-Acute COVID-19 Syndrome | 05/25 | 06/25 | | |
